TORL BioTherapeutics Taps Aran Maree, M.D. as CEO
TORL BioTherapeutics LLC, a biotechnology company specializing in oncology at the clinical stage, today revealed a leadership change to prepare the Company for its upcoming growth phase.
Starting May 1, 2026, Aran Maree, M.D., is named Chief Executive Officer (CEO) and a member of the Board. Dr. Maree takes over from Mark Alles, who will still assist the Company as Chairman of the Board.
"TORL was established to identify, create, and bring to market leading-edge cancer treatments." "Considering Aran's remarkable, multi-decade career in the industry and the leadership he's shown as TORL's inaugural Chief Medical Officer, both the Board and I firmly believe he possesses the experience, insight, and enthusiasm to steer TORL through and past this vital upcoming stage of clinical achievements," states Mark J. Alles, Chairman of TORL BioTherapeutics.
"His selection signifies a strategically orchestrated leadership shift aimed at preparing TORL for expansion and operational efficiency, and I am eager to collaborate further with Aran and the entire TORL team to enhance patient results," adds Mark J. Alles.
Also Read: How This Techie Turned Visa Struggles into Startup Success
Aran Maree, M.D., Chief Executive Officer states, "I’m privileged to take on the CEO position with the backing of Mark Alles and the TORL Board as we progress Ixo-V toward its initial regulatory submissions and develop our early-stage pipeline. TORL aims to create antibody-driven treatments that significantly enhance the quality of life for individuals with cancer. With our growing leadership team, we are in a strong position to fulfill our mission.
Also Read: 5 Key Leadership Appointments across Global Firms in March 2026
Dr. Maree's joining is a component of a larger strategic initiative aimed at reinforcing TORL's leadership group and improving governance as the Company moves toward late-stage development and possible commercialization.
Also Read: How US–China Tariffs Are Disrupting Textile Trade
The search for the next CMO of TORL is currently in progress. In early 2026, as part of this succession strategy, TORL designated several accomplished leaders for new positions aimed at enhancing the organization's readiness for upcoming growth. Collectively, TORL's leadership team possesses extensive experience in constructing biotechnology firms and creating transformative therapies for patients facing significant unmet medical needs.